Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data on breast cancer discussed by D. Sarid and colleagues
January 8th, 2009
In this recently published study, investigators in Tel Aviv, Israel conducted a study "To correlate p53 and ErbB receptors status with disease-free survival (DFS) and overall survival (OS) in locally advanced breast cancer. Sixty patients were included in a single-center, open-label, phase II trial (1998-2003)." "Analysis of Erb receptors and p53 status and estrogen receptor/progesterone receptor data were available for 33 patients. Neoadjuvant epirubicin 75 mg/m(2) and paclitaxel 175-200 mg/m(2) were administered every 21 days. The patients underwent surgery and radiation therapy and adjuvant chemolhormonotherapy. Approximately two thirds of the patients demonstrated...
Source: Women's Health Weekly (2009-01-08)
|
